MaxCyte, Inc., a leading provider of cell-engineering platform technologies, announced the signing of a clinical and commercial license with Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines.Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and programme-related milestone payments.Doug Doerfler, president and CEO of MaxCyte, said: "We are delighted to support Sana's ex vivo cell therapy programmes and recognize the potential of the company's novel hypoimmune cell platform to advance treatments for serious diseases. This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments."MaxCyte's ExPERT instrument portfolio represents the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies.
